Revenue Estimates Analysis: PDL BioPharma, Inc. (NASDAQ:PDLI)


PDL BioPharma, Inc. (NASDAQ:PDLI) will report its next earnings on Feb 20 – Feb 24 (Est.). The company reported the earnings of $0.11/Share in the last quarter where the estimated EPS by analysts was $0.08/share. The difference between the expected and actual EPS was $0.03/share, which represents an Earnings surprise of 37.5%.

In case of Revenue Estimates, 2 analysts have provided their consensus Average Revenue Estimates for PDL BioPharma, Inc. as 63.87 Million. According to these analysts, the Low Revenue Estimate for PDL BioPharma, Inc. is 61.6 Million and the High Revenue Estimate is 66.13 Million. The company had Year Ago Sales of 178.06 Million.

Some buy side analysts are also providing their Analysis on PDL BioPharma, Inc., where 0 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 2 said it’s a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. 2 Analysts reported that the Price Target for PDL BioPharma, Inc. might touch $4 high while the Average Price Target and Low price Target is $3.5 and $3 respectively.

To analyze a stock, one should look for Upgrades and Downgrades of a stock. PDL BioPharma, Inc. got Upgrade on 20-Jan-11 where investment firm RBC Capital Mkts Upgrade the stock from Sector Perform to Outperform.

PDL BioPharma, Inc. closed its last trading session at $2.29 with the loss of -4.37%. The Market Capitalization of the company stands at 362.58 Million. The Company has 52-week high of $3.95 and 52-week low of $2.14. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -29.08% where SMA50 and SMA200 are -31.37% and -31.55% respectively. The Company Touched its 52-Week High on Dec 17, 2015 and 52-Week Low on Nov 30, 2016.

The Relative Volume of the company is 2.6 and Average Volume (3 months) is 2.03 million. PDL BioPharma, Inc. P/E (price to earnings) ratio is 2.06 and Forward P/E ratio of 10.84.

The company shows its Return on Assets (ROA) value of 16.1%. The Return on Equity (ROE) value stands at 23.9%. While it’s Return on Investment (ROI) value is 37.8%.

While looking at the Stock’s Performance, PDL BioPharma, Inc. currently shows a Weekly Performance of -27.72%, where Monthly Performance is -31.99%, Quarterly performance is -24.74%, 6 Months performance is -37.78% and yearly performance percentage is -37.79%. Year to Date performance value (YTD perf) value is -36.21%. The Stock currently has a Weekly Volatility of 7.88% and Monthly Volatility of 5.79%.